AM 36

Drug Profile

AM 36

Alternative Names: AM36

Latest Information Update: 31 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zenyth Therapeutics
  • Class Neuroprotectants
  • Mechanism of Action Antioxidants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 23 Aug 2004 Discontinued - Preclinical for Stroke in Australia (unspecified route)
  • 30 Jun 2003 A preclinical study has been added to the Neurological diorders pharmacodynamics section
  • 15 Jan 2003 AM 336 is available for licensing []
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top